Complement Therapeutics

Complement Therapeutics (CTx) has enrolled the first patient in its study of people diagnosed with geographic atrophy (GA).  The research will support the clinical development of CTx001, CTx’s lead gene therapy asset for the treatment of GA, by enabling the identification of patients with complement-driven AMD for future interventional studies.  Also called late dry age-related macular […]

Biotechnology company Complement Therapeutics (CTx) has formed a Clinical & Scientific Advisory Board to help accelerate the development of its pipeline of therapeutics targeting complement-mediated diseases. The company’s lead investigational product, CTx001, is a gene therapy for dry age-related macular degeneration/geographic atrophy, which is a leading cause of blindness. The company hopes to evaluate CTx001 […]